Skip to main content

FDA Approvals

Tivdak First Antibody–Drug Conjugate FDA Approved for Recurrent or Metastatic Cervical Cancer

Rezurock Novel Oral Therapy FDA Approved for Chronic Graft-versus-Host Disease

Jakafi a New Treatment Option for Chronic Graft-versus-Host Disease

Welireg FDA Approved for 3 Tumor Types Associated with von Hippel-Lindau Disease

Opdivo First FDA-Approved Immunotherapy for First-Line Treatment of Advanced Gastric Cancer

Keytruda Received FDA Approval for First-Line Treatment of HER2-Positive Advanced Gastric Cancer

Trodelvy Receives New Indication for Advanced Urothelial Cancer

Sarclisa Receives New Indication for Relapsed or Refractory Multiple Myeloma

FDA Alert: Pepaxto (Melphalan Flufenamide) Associated with Increased Risk of Death in Postmarketing Clinical Trial

Jemperli First FDA-Approved Immunotherapy for Advanced Endometrial Cancer with dMMR Biomarker

Page 8 of 20
Results 71 - 80 of 200